Molecular predictors of response to antiangiogenesis therapies

Armin Gerger, Melissa LaBonte, Heinz-Josef Lenz, Melissa LaBonte Wilson

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Angiogenesis is a crucial component of tumor growth and metastasis. Targeting the vascular endothelial growth factor pathway represents therapeutic potentials for treating cancer. To date, 3 Food and Drug Administration-approved agents targeting angiogenesis have been developed, bevacizumab, sunitinib, and sorafenib. However, no validated biomarkers are available to identify those patients who are likely to benefit from antiangiogenesis therapy. Molecular biomarker research in antiangiogenesis inhibition is an actively growing field. Although current data are extremely promising, it is still uncertain which biomarker(s) can reliably predict their efficacy. With increasing numbers of inhibitors being developed, the need for biomarkers is more critical than ever. This review will focus on translational research that strives to identify molecular biomarkers (tissue, circulating and genomic) for approved antiangiogenesis therapies that can indicate benefit, resistance, and toxicity.

Original languageEnglish
Pages (from-to)134-41
Number of pages8
JournalThe Cancer Journal
Volume17
Issue number2
DOIs
Publication statusPublished - 24 Mar 2011

Keywords

  • Angiogenesis Inhibitors
  • Humans
  • Neovascularization, Pathologic
  • Signal Transduction
  • Treatment Outcome
  • Tumor Markers, Biological
  • Vascular Endothelial Growth Factor A

Fingerprint Dive into the research topics of 'Molecular predictors of response to antiangiogenesis therapies'. Together they form a unique fingerprint.

  • Cite this